Is Chemotherapy More Effective After Prior Immunotherapy? (BMIC-029)
Dr. Jack West presents early data suggesting that chemotherapy may be more effective after prior immunotherapy than otherwise. (5:02)
Tag Archives: pembrolizumab
New Insights on Acquired Resistance to Immune Checkpoint Inhibitors for NSCLC: Implications for Treatment Options (BMIC-028)
Dr. Jack West reviews new data on patterns of acquired resistance after a response to immune checkpoint inhibitors for advanced NSCLC, along with the clinical implications of various options based on these observations. (11:33)
Chemo-Immunotherapy in Non-Squamous NSCLC: Has the KEYNOTE-189 Trial Defined a Clear Standard of Care? (BMIC-022)
Dr. Jack West reviews the results and pending questions of the KEYNOTE-189 trial of chemotherapy with or without pembrolizumab (KEYTRUDA) as first line therapy for advanced non-squamous NSCLC, as well as how they change the treatment landscape. (8:13)
Are the PD-1/PD-L1 Immune Checkpoint Inhibitors Completely Interchangeable in Lung Cancer Management? (BMIC-015)
Dr. Jack West addresses the question of whether the data with various PD-1 and PD-L1 inhibitors in lung cancer management can be viewed as a class effect and whether these immune checkpoint inhibitors should be considered interchangeable. (5:52)
Chemo/Immunotherapy Data Increasingly Compelling with Additional Follow-Up (BMIC-009)
Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer follow-up of the KEYNOTE-021g trial. (6:55)
Is There Still a Value in Testing for PD-L1 Expression in Advanced NSCLC Today? (BMIC-005)
Dr. Jack West explains the potential value PD-L1 expression during the initial workup of patients with advanced NSCLC, in the face of a broad FDA approval for chemo/immunotherapy regardless of PD-L1 status in patients with advanced non-squamous NSCLC. (2:40)